Get the Stockscreener App
171.84
0.13%
-0.30
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $171.84, with a volume of 84,180.
It is down -0.13% in the last 24 hours and up +12.62% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$172.14
Open:
$171.27
24h Volume:
84,180
Relative Volume:
0.09
Market Cap:
$19.04B
Revenue:
$9.54B
Net Income/Loss:
$841.00M
P/E Ratio:
23.10
EPS:
7.44
Net Cash Flow:
$1.02B
1W Performance:
+1.86%
1M Performance:
+12.62%
6M Performance:
+12.38%
1Y Performance:
+35.65%
1-Day Range:
$171.01
$172.51
1-Week Range:
$166.15
$172.64
52-Week Range:
$123.66
$172.64
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
171.83 | 19.04B | 9.54B | 841.00M | 1.02B | 7.44 |
|
TMO
Thermo Fisher Scientific Inc
|
537.07 | 205.72B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
212.22 | 149.54B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
136.32 | 39.02B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
460.04 | 37.08B | 3.90B | 887.87M | 808.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
195.16 | 34.17B | 15.41B | 1.37B | 2.11B | 7.50 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
New York State Teachers Retirement System Cuts Position in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics (NYSE:DGX) Hits New 52-Week HighTime to Buy? - MarketBeat
Principal Financial Group Inc. Purchases 104,495 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Shares Bought by Van ECK Associates Corp - MarketBeat
Vontobel Holding Ltd. Has $7.14 Million Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Chevy Chase Trust Holdings LLC Has $15.36 Million Stake in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
In vitro diagnostics Market Poised for Significant Growth to Reach value of USD 133.24 Billion from 2025 to 2034 - GlobeNewswire Inc.
Quest Diagnostics stock hits 52-week high at $171.42 By Investing.com - Investing.com Nigeria
Quest Diagnostics stock hits 52-week high at $171.42 - Investing.com
Quest Diagnostics Incorporated (NYSE:DGX) Shares Bought by Kentucky Retirement Systems Insurance Trust Fund - MarketBeat
Is There An Opportunity With Quest Diagnostics Incorporated's (NYSE:DGX) 50% Undervaluation? - Yahoo Finance UK
Rhumbline Advisers Sells 8,647 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by Empowered Funds LLC - MarketBeat
Savant Capital LLC Raises Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
MOKAN Wealth Management Inc. Makes New Investment in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Sheaff Brock Investment Advisors LLC Makes New Investment in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Stock Holdings Reduced by Avestar Capital LLC - MarketBeat
How Is Quest Diagnostics' Stock Performance Compared to Other Diagnostics & Research Stocks? - MSN
Earnings Preview: What to Expect From Quest Diagnostics' Report - MSN
Quest Diagnostics (NYSE:DGX) Sets New 12-Month HighHere's What Happened - MarketBeat
Palumbo Wealth Management LLC Acquires 2,396 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
State of Alaska Department of Revenue Trims Holdings in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
WCM Investment Management LLC Acquires 1,647 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Grail shares jump on partnership with Quest Diagnostics - Mugglehead
SVP for Diagnostic Services Plewman Patrick was granted 2,042 shares, increasing direct ownership by 12% to 18,402 units (SEC Form 4) - Quantisnow
Weatherly Asset Management L. P. Sells 2,930 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Cambiar Investors LLC Sells 9,196 Shares of Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Yousif Capital Management LLC Has $2.77 Million Position in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Quest Diagnostics Unveils Future Roadmap: Lab Market Strategy and Growth Plans Take Center Stage - StockTitan
Grail rallies 30% in wake of Quest agreement (GRAL:NASDAQ) - Seeking Alpha
Grail and Quest Diagnostics to offer Galleri test to US physicians - Medical Device Network
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Grail Shares Spiked Wednesday: What's Going On? - Benzinga
Kentucky Trust Co Buys Shares of 1,506 Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Argus Adjusts Price Target on Quest Diagnostics to $185 From $175, Maintains Buy Rating - Marketscreener.com
Grail And Quest Diagnostics Provide Grail's Galleri Multi-Cancer Early Detection (MCED) Test - Marketscreener.com
Revolutionary Cancer Detection Test Now Available at Quest Labs NationwideEarly Detection for 50+ Types - StockTitan
Self-Testing Market Projected To Witness Substantial Growth, 2025-2032:Quest Diagnostics, Bionime Corporation, - EIN News
Quest Diagnostics Incorporated (NYSE:DGX) SVP Mark E. Delaney Sells 403 Shares - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Director Sells $205,712.50 in Stock - MarketBeat
GHP Investment Advisors Inc. Boosts Stake in Quest Diagnostics Incorporated (NYSE:DGX) - MarketBeat
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term - Nasdaq
Quest Diagnostics Stock to Gain From Innovation Amid Industry Threats - Nasdaq
Quest Diagnostics (NYSE:DGX) Stock Rating Lowered by StockNews.com - MarketBeat
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):